Rupatadine for the treatment of urticaria

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 13, 2013, Pages 1807-1813

  Nettis, Eustachio ^a   Delle Donne, Pantalea ^a   Di Leo, Elisabetta ^a   Calogiuri, Gian Franco ^b   Ferrannini, Antonio ^a   Vacca, Angelo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b Pneumologic Hospital A Galateo   (Italy)

Author keywords

Rupatadine; Safety; Tolerability; Urticaria

Indexed keywords

ERYTHROMYCIN; KETOCONAZOLE; LORAZEPAM; MOXIFLOXACIN; PLACEBO; RUPATADINE;

ACQUIRED COLD URTICARIA; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD PRESSURE; CHRONIC URTICARIA; CLINICAL EFFECTIVENESS; COLD URTICARIA; DRUG ABSORPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; GRAPEFRUIT JUICE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PULSE RATE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA;

EID: 84881637537     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.813481     Document Type: Article

References (34)

1. Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003;33(9):1305-24
2. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011;128(6):1139-50
3. Izquierdo I, Merlos M, Garća-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc) 2003;39(6):451-68
4. Solans A, Carbó ML, Peña J, et al. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Clin Ther 2007;29(5):900-8
5. Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997;280(1):114-21
6. Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother 2006;7(14):1989-2001
7. Kanani A, Schellenberg R, Warrington R. Urticaria and angioedema. Allergy Asthma Clin Immunol 2011;7:(Suppl 1):S9
8. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2) LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64(10):1417-26
9. Medic N, Desai A, Komarow H, et al. Examination of the role of TRPM8 in human mast cell activation and its relevance to the etiology of cold-induced urticaria. Cell Calcium 2011;50(5):473-80
10. Fonacier LS, Dreskin SC, Leung DY. Allergic skin diseases. J Allergy Clin Immunol 2010;125(2 Suppl 2):S138-49
11. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2) LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64(10):1427-43
12. Izquierdo I, Nieto C, Ramis J, et al. Pharmacokinetic and dose linearity of rupatadine fumarate in healthy volunteers. Meth Find Exp Clin Pharmacol 1997;19(Suppl A):189
13. Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs 2007;67(3):457-74
14. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011;66:317-30
15. Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006;27(2):96-9
16. Salmun LM. Antihistamines in late-phase clinical development for allergic disease. Expert Opin Investig Drugs 2002;11(2):259-73
17. Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007;17(3):223-8
18. Gimenez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy 2007;62(5):539-46
19. Giménez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol 2009;23(9):1088-91
20. Church MK, Máspero JF, Maurer M, et al. The Scope of Pharmacological and Clinical Effects of Modern Antihistamines, With a Special Focus on Rupatadine: proceedings from a Satellite Symposium held at the 21st World Allergy Congress; 8 December 2009; Buenos Aires. World Allergy Organ J 2010;3(4 Suppl):S1-S16
21. Church MK. Efficacy and tolerability of rupatadine at four times the recommended dose against histamineand platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. Br J Dermatol 2010;163(6):1330-2
22. Maiti R, Jaida J, Raghavendra BN, et al. Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. J Drugs Dermatol 2011;10(12):1444-50
23. Kim H, Lynde C. Impact of desloratadine on symptoms and quality of life in subjects with chronic idiopathic urticaria: a multicenter, practice-based study. Arch Drug Inf 2008;1(2):63-9
24. Wanderer AA. Cold urticaria syndromes: historical background, diagnostic classification, clinical and laboratory characteristics, pathogenesis, and management. J Allergy Clin Immunol 1990;85(6):965-81
25. Lee CW, Sheffer AL. Primary acquired cold urticaria. Allergy Asthma Proc 2003;24:9-12
26. Di Leo E, Nettis E, Cassano N, et al. Treatment of acquired cold urticaria with rupatadine. Allergy 2009;64(9):1387-8
27. Metz M, Scholz E, Ferrán M, et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 2010;104(1):86-92
28. Valero A, de la Torre F, Castillo JA, et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. Drug Saf 2009;32(1):33-42
29. Garća-Gea C, Ballester MR, Mart́nez J, et al. Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study. Br J Clin Pharmacol 2010;69(6):663-74
30. Vuurman E, Theunissen E, van Oers A, et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum Psychopharmacol 2007;22(5):289-97
31. Barbanoj MJ, Garća-Gea C, Morte A, et al. Central and peripheral evaluation of rupatadine, a new antihistamine/plateletactivating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 2004;50(4):311-21
32. Barbanoj MJ, Garća-Gea C, Antonijoan R, et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol 2006;21(1):13-26
33. Donado E, Izquierdo I, Pérez I, et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines. Br J Clin Pharmacol 2010;69(4):401-10
34. Caballero R, Valenzuela C, Longobardo M, et al. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels. Br J Pharmacol 1999;128(5):1071-81